Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209 On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original article
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f7e040c8333d42af9a814346b023d546 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:f7e040c8333d42af9a814346b023d546 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:f7e040c8333d42af9a814346b023d5462021-12-02T06:18:05ZFactors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]1178-2013https://doaj.org/article/f7e040c8333d42af9a814346b023d5462019-07-01T00:00:00Zhttps://www.dovepress.com/httpswwwdovepresscomcorrigendum-factors-affecting-the-pharm-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209 On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original articleWu HInfante JRKeedy VLJones SFChan EBendell JCLee WKirschbrown WPZamboni BAIkeda SKodaira HRothenberg MLBurris III HAZamboni WCDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 5751-5752 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Wu H Infante JR Keedy VL Jones SF Chan E Bendell JC Lee W Kirschbrown WP Zamboni BA Ikeda S Kodaira H Rothenberg ML Burris III HA Zamboni WC Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] |
| description |
Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209 On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original article |
| format |
article |
| author |
Wu H Infante JR Keedy VL Jones SF Chan E Bendell JC Lee W Kirschbrown WP Zamboni BA Ikeda S Kodaira H Rothenberg ML Burris III HA Zamboni WC |
| author_facet |
Wu H Infante JR Keedy VL Jones SF Chan E Bendell JC Lee W Kirschbrown WP Zamboni BA Ikeda S Kodaira H Rothenberg ML Burris III HA Zamboni WC |
| author_sort |
Wu H |
| title |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] |
| title_short |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] |
| title_full |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] |
| title_fullStr |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] |
| title_full_unstemmed |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] |
| title_sort |
factors affecting the pharmacokinetics and pharmacodynamics of pegylated liposomal irinotecan (ihl-305) in patients with advanced solid tumors [corrigendum] |
| publisher |
Dove Medical Press |
| publishDate |
2019 |
| url |
https://doaj.org/article/f7e040c8333d42af9a814346b023d546 |
| work_keys_str_mv |
AT wuh factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT infantejr factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT keedyvl factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT jonessf factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT chane factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT bendelljc factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT leew factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT kirschbrownwp factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT zamboniba factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT ikedas factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT kodairah factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT rothenbergml factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT burrisiiiha factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum AT zamboniwc factorsaffectingthepharmacokineticsandpharmacodynamicsofpegylatedliposomalirinotecanihl305inpatientswithadvancedsolidtumorscorrigendum |
| _version_ |
1718400029767499776 |